To include your compound in the COVID-19 Resource Center, submit it here.

Kosan, Roche cancer deal

KOSN granted Roche (SWX:ROCZ) global rights to commercialize KOSN's KOS-862 epothilone

Read the full 114 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE